22348-38-5

Usage

Uses

Used in Pharmaceutical Industry:
Cis-4-Methylamino-cyclohexanol was previously utilized as a muscle relaxant and anesthetic agent for its ability to depress the central nervous system and induce muscle relaxation. However, due to its high potential for abuse and addiction, its use has been discontinued, and it is now classified as a Schedule I controlled substance in the United States, indicating no accepted medical use and a high potential for abuse. Despite its therapeutic potential, the risk of abuse has resulted in limited use and availability in the pharmaceutical industry.

InChI:InChI=1/C7H15NO/c1-8-6-2-4-7(9)5-3-6/h6-9H,2-5H2,1H3/t6-,7-

Upstream product

• 579-58-8 N-methyl-(4-acetamido)phenol 
• 167081-25-6 cis-(4-hydroxycyclohexyl)carbamic acid tert-butyl ester 

Downstream Products

• 561307-54-8 tert-butyl methyl(4-oxocyclohexyl)carbamate 
• 798533-03-6 cis-1-(4-hydroxy-cyclohexyl)-3-[4-methoxy-7-(tetrahydro-pyran-4-yl)-benzothiazol-2-yl]-1-methyl-urea 
• 941598-28-3 cis-1-(methanesulphonyloxy)-4-(N-methanesulphonyl-N-methyl-amino)-cyclohexane 

Relevant academic research and scientific papers

6-SUBSTITUTED ISOQUINOLINE DERIVATIVES

The present invention relates to 6-substituted isoquinoline derivatives having the general Formula I wherein X is O, S or NH; Y is OH or NH2; m is 0, 1 or 2; n is 0 or 1; o is 0 or 1; R1 is H, when Y is NH2; or R1 is H, (C1-4)alkyl or halogen, when Y is OH; R2 and R3 are independently H, (C1-4)alkyl or halogen; R4 is H or (C1-6)alkyl, optionally substituted with halogen, (C3-7)cycloalkyl, (C6-10)aryl or a saturated 5- or 6-membered heterocyclic ring comprising 1-3 heteroatoms independently selected from O, S and N, the (C6-10)aryl and heterocyclic ring being optionally substituted with (C1-4)alkyl, (C1-4)alkyloxy or halogen; R5 is H or (C1-4)alkyl; or a pharmaceutically acceptable salt thereof, with the proviso that the compounds of Formula I wherein X is O, Y is OH , n is 0 and m+o=2 are excluded, to pharmaceutical compositions comprising the same, as well as to the use of said 6-substituted isoquinoline derivatives for the preparation of a medicament for the treatment of ROCK-I related disorders such as glaucoma, hypertension and atherosclerosis.